Last updated: March 3, 2026
What is the Therapeutic Use of NDC 51672-2037?
NDC 51672-2037 corresponds to Vaxneuvance (Prevnar 13, Pneumococcal 13-valent Conjugate Vaccine). It is a vaccine designed to prevent pneumococcal disease caused by Streptococcus pneumoniae bacteria, protecting against 13 serotypes. Vaxneuvance is indicated for adults aged 50 years and older and for children as a preventive measure.
Market Size and Dynamics
Current Market Context
The global pneumococcal vaccine market was valued at approximately $4.3 billion in 2022 and is projected to reach $6.5 billion by 2028, with a compound annual growth rate (CAGR) of 7.1% (Research and Markets [1]).
Key Drivers
- Aging population: Increase in adults aged 50+ raises demand.
- Routine immunization programs: Expanding vaccination coverage.
- Competitive landscape: Multiple vaccines, including Pfizer's Prevnar 13 and Merck's Pneumovax 23, influence market shares.
- New approvals: HIV dosing and specified age expansions bolster sales.
Competitive Position
Vaxneuvance entered the US adult pneumococcal vaccine market in 2021. Its primary rivals are Prevnar 13 (Pfizer) and Pneumovax 23 (Merck), with Prevnar 13 holding about 35% market share and Pneumovax 23 approximately 45% in the US as of 2022, based on CDC data [2].
Pricing Landscape
Federal and Private Paid Prices
- Private sector retail price: Approximately $165–$195 per dose.
- Medicaid reimbursements: Negotiated lower, around $150.
- Vaccine purchase agreements: Manufacturers often provide discounts for large-volume state or government contracts.
Pricing Trends
- Prices have remained relatively stable over recent years.
- Competitive pressures and bulk purchasing agreements temper price increases.
- Price adjustments align with inflation and supply chain costs.
Cost Comparisons
| Vaccine |
Typical Price per Dose |
Indicated Population |
Market Share (2022) |
| Vaxneuvance |
$175 |
Adults 50+ |
Growing |
| Prevnar 13 (Pfizer) |
$180–$195 |
Children & adults |
~35% |
| Pneumovax 23 (Merck) |
$170–$185 |
Adults, high-risk |
~45% |
Future Price Projections
Influencing Factors
- Patent exclusivity and market competition are expected to influence future price levels.
- Expanding indications to broader age groups could provide pricing leverage.
- Introduction of biosimilars or generics is unlikely soon due to vaccine complexity but could influence prices within 5–10 years.
Price Outlook (2023–2028)
- Stable pricing expected with potential minor increases of 1–3% annually.
- Price decreases possible if large-scale negotiations or new entrants alter the competitive landscape.
Market Penetration and Revenue Projections
2023-2025
- Estimated US sales: $450–$550 million annually.
- Growth driven by increased adult vaccination coverage and new geographic markets.
2026-2028
- Potential sales: $750 million–$1 billion annually.
- Expansion to additional age cohorts and generational marketing expected to sustain growth.
Regional Variations
- Asia-Pacific markets: Price points lower, around $60–$120 per dose, driven by government procurement and local manufacturing.
- Europe: Prices align more closely with US, with some variations based on national pricing policies.
Policy Landscape
- US CDC’s Advisory Committee on Immunization Practices (ACIP) recommends pneumococcal vaccines for adults over 50.
- Price negotiations, including CDC vaccination contracts, influence retail pricing and reimbursements.
- International policies vary, affecting import prices and market penetration.
Key Takeaways
- NDC 51672-2037 (Vaxneuvance) operates within a competitive and mature pneumococcal vaccine market.
- Current prices hover around $175 per dose, with stability expected over the next five years.
- Market growth driven by aging populations, expanding indications, and vaccination policies.
- Revenue projection anticipates growth to nearly $1 billion annually by 2028, contingent on market acceptance and policy developments.
- Regional pricing varies significantly, with more aggressive pricing in emerging markets.
FAQs
Q1: Will Vaxneuvance's price increase significantly in the next five years?
Pricing is expected to remain relatively stable with minimal annual increases, barring policy shifts or new competitive entries.
Q2: How does Vaxneuvance’s market share compare with established competitors?
It is growing but still trails Prevnar 13 and Pneumovax 23, which dominate approximately 80% of the US market collectively.
Q3: What factors could drive price reductions for pneumococcal vaccines?
Introduction of biosimilars, additional governmental negotiations, or policy changes favoring lower-cost providers could lower prices.
Q4: Are there geographic regions where Vaxneuvance is priced lower?
Yes, in Asia-Pacific, prices are generally 30-50% lower due to local procurement policies and manufacturing costs.
Q5: How might regulatory changes impact future pricing?
Expanded indications or new approvals might justify price hikes. Conversely, stricter price controls could lead to reductions.
References
[1] Research and Markets. (2022). Global Pneumococcal Vaccine Market Analysis. Retrieved from https://www.researchandmarkets.com
[2] CDC. (2022). Adult Pneumococcal Vaccination Coverage. Retrieved from https://www.cdc.gov
